Wedbush Reiterates Outperform on Inozyme Pharma, Maintains $15 Price Target

Inozyme Pharma +0.22%

Inozyme Pharma

INZY

4.57

+0.22%

Wedbush analyst David Nierengarten reiterates Inozyme Pharma (NASDAQ: INZY) with a Outperform and maintains $15 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via